Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients.

ABSTRACT:

Introduction

The current management of hyperphosphatemia with phosphate binders is associated with insufficient phosphorus control and a significant pill burden. Tenapanor, a first-in-class, phosphate absorption inhibitor, is expected to control phosphorus and decrease pill burden because of its small pill size and twice daily dosing regimen. This study evaluated tenapanor effectiveness on reducing the phosphate binder pill burden during a 26-week treatment period in Japanese hemodialysis patients.

Methods

In this multicenter, open-label, single-arm study, hemodialysis patients whose serum phosphorus level was 3.5 to 7.0 mg/dl received tenapanor 30 mg twice daily orally added to their phosphate binder regimen. The phosphate binder dosage was adjusted to achieve a serum phosp

SUBMITTER: Akizawa T 

PROVIDER: S-EPMC8418975 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature